PDS Biotechnology Corporation (PDSB)
Largest Insider Buys in Sector
PDSB Stock Price History Chart
PDSB Stock Performance
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for …
Insider Activity of PDS Biotechnology Corporation
Over the last 12 months, insiders at PDS Biotechnology Corporation have bought $0 and sold $0 worth of PDS Biotechnology Corporation stock.
On average, over the past 5 years, insiders at PDS Biotechnology Corporation have bought $238,313 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,100 shares for transaction amount of $27,860 was made by HILL MATTHEW C () on 2021‑12‑13.
List of Insider Buy and Sell Transactions, PDS Biotechnology Corporation
| 2021-12-13 | 3,100 0.012% | $8.99 | $27,860 | -41.56% | ||||
| 2021-06-16 | 10,000 0.0456% | $9.88 | $98,778 | -4.17% | ||||
| 2021-06-15 | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | ||||
| 2021-06-15 | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | ||||
| 2021-06-15 | 17,647 0.0704% | $8.50 | $150,000 | -2.50% | ||||
| 2021-06-15 | 11,764 0.0469% | $8.50 | $99,994 | -2.50% | ||||
| 2018-03-22 | Sale | Chief Scientific Officer | 5,000 0.0161% | $16.41 | $82,050 | -94.86% | ||
| 2018-03-21 | Sale | Chief Scientific Officer | 5,000 0.0159% | $16.52 | $82,600 | -94.94% | ||
| 2018-03-20 | Sale | Chief Scientific Officer | 10,000 0.0322% | $16.47 | $164,700 | -94.85% | ||
| 2018-03-19 | Sale | Chief Scientific Officer | 5,000 0.0161% | $16.59 | $82,950 | -94.88% | ||
| 2018-03-02 | Sale | President and CEO | 5,000 0.0159% | $15.08 | $75,400 | -94.24% | ||
| 2018-03-01 | Sale | President and CEO | 5,000 0.0161% | $14.95 | $74,725 | -94.13% | ||
| 2018-02-23 | Sale | President and CEO | 5,000 0.0158% | $15.37 | $76,850 | -94.34% | ||
| 2018-02-22 | Sale | Chief Scientific Officer | 5,000 0.0151% | $14.49 | $72,450 | -94.25% | ||
| 2018-02-22 | Sale | President and CEO | 5,000 0.0161% | $15.42 | $77,100 | -94.25% | ||
| 2018-02-21 | Sale | Chief Scientific Officer | 10,000 0.0304% | $13.82 | $138,200 | -93.91% | ||
| 2018-02-20 | Sale | Chief Scientific Officer | 10,000 0.0323% | $13.79 | $137,850 | -93.48% | ||
| 2018-02-02 | Sale | President and CEO | 5,000 0.0163% | $12.96 | $64,800 | -92.76% | ||
| 2018-02-01 | Sale | President and CEO | 5,000 0.0159% | $13.05 | $65,250 | -92.97% | ||
| 2018-01-03 | Sale | President and CEO | 5,000 0.0162% | $10.11 | $50,550 | -90.32% |
Insider Historical Profitability
| HEALY JAMES | director | 2852711 7.7478% | $3.23 | 2 | 0 | <0.0001% |
| Hove Anders D | director | 2021917 5.4914% | $3.23 | 1 | 0 | <0.0001% |
| BARER SOL J | director | 632810 1.7187% | $3.23 | 1 | 0 | <0.0001% |
| Bloomquist DeLyle W | 193888 0.5266% | $3.23 | 1 | 0 | <0.0001% | |
| Einhorn Andrew J. | Chief Financial Officer | 81941 0.2225% | $3.23 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $7.4M | 5.09 | 1.87M | -0.74% | -$55,483.56 | <0.0001 | |
| The Vanguard Group | $6.29M | 4.33 | 1.59M | +5.46% | +$325,254.56 | <0.0001 | |
| Geode Capital Management | $2.59M | 1.78 | 654,185 | +3.31% | +$83,094.84 | <0.0001 | |
| State Street | $2.21M | 1.52 | 557,320 | +0.96% | +$20,940.48 | <0.0001 | |
| Inspirion Wealth Advisors LLC | $1.41M | 0.97 | 354,977 | +5.46% | +$72,796.68 | 0.25 |